‘ Is life worth living? It all depends on the liver’ (American philosopher William James [1842—1910]) Non-alcoholic fatty liver disease (NAFLD) is currently the most frequent global liver disease.1 ...

Data from experimental studies have demonstrated that marine omega-3 polyunsaturated fatty acids (O3FAs) have anti-inflammatory and anticancer properties. In the last decade, large-scale randomised ...

Iron deficiency anaemia (IDA) is a major cause of morbidity and burden of disease worldwide. It can generally be diagnosed by blood testing and remedied by iron replacement therapy (IRT) using the ...

Transcription factors of the family p53 have emerged as an important set of tumour suppressors, able to regulate various cell functions like cell cycle arrest, differentiation, DNA repair, apoptosis ...

Introduction Iron deficiency anaemia (IDA) is common with BSG guidance suggesting Gastrointestinal (GI) blood loss from colonic or gastric cancer, and malabsorption in coeliac disease are the most ...

Background Chronic inflammation and elevated reactive oxygen species are key contributors to hepatocellular carcinoma (HCC) ...

A high adenoma detection rate (ADR) is vital for effective colorectal cancer (CRC) screening, but evidence suggests limited additional benefit beyond a certain threshold. In a pooled analysis of five ...

Knowledge on SARS-CoV-2 infection and its resultant COVID-19 in liver diseases has rapidly increased during the pandemic. Hereby, we review COVID-19 liver manifestations and pathophysiological aspects ...

Irritable bowel syndrome (IBS) remains one of the most common gastrointestinal disorders seen by clinicians in both primary and secondary care. Since publication of the last British Society of ...

Background Hepatocellular carcinoma (HCC) is the sixth most common cancer and the fourth leading cause of cancer-related death worldwide. Effective early diagnosis is hampered by the lack of ...

Background and aims: This study evaluates the long-term safety of infliximab in patients with inflammatory bowel disease (IBD) treated with the drug over a 14-year period. Methods: The medical records ...

Objective We evaluated the histamine 1 receptor antagonist ebastine as a potential treatment for patients with non-constipated irritable bowel syndrome (IBS) in a randomised, placebo-controlled phase ...